25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

MoonLake Immunotherapeutics
Buy, Hold or Sell?

Let's analyze MoonLake Immunotherapeutics together

I guess you are interested in MoonLake Immunotherapeutics. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of MoonLake Immunotherapeutics. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about MoonLake Immunotherapeutics

I send you an email if I find something interesting about MoonLake Immunotherapeutics.

1. Quick Overview

1.1. Quick analysis of MoonLake Immunotherapeutics (30 sec.)










1.2. What can you expect buying and holding a share of MoonLake Immunotherapeutics? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$7.86
Expected worth in 1 year
$7.95
How sure are you?
40.0%

+ What do you gain per year?

Total Gains per Share
$0.09
Return On Investment
0.2%

For what price can you sell your share?

Current Price per Share
$44.07
Expected price per share
$38.38 - $56.00
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of MoonLake Immunotherapeutics (5 min.)




Live pricePrice per Share (EOD)
$44.07
Intrinsic Value Per Share
$-23.94 - $-28.45
Total Value Per Share
$-16.08 - $-20.60

2.2. Growth of MoonLake Immunotherapeutics (5 min.)




Is MoonLake Immunotherapeutics growing?

Current yearPrevious yearGrowGrow %
How rich?$495.5m$279.1m$243.6m46.6%

How much money is MoonLake Immunotherapeutics making?

Current yearPrevious yearGrowGrow %
Making money-$20.1m-$12m-$8.1m-40.3%
Net Profit Margin-26,738.7%0.0%--

How much money comes from the company's main activities?

2.3. Financial Health of MoonLake Immunotherapeutics (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  

3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of MoonLake Immunotherapeutics?

Welcome investor! MoonLake Immunotherapeutics's management wants to use your money to grow the business. In return you get a share of MoonLake Immunotherapeutics.

First you should know what it really means to hold a share of MoonLake Immunotherapeutics. And how you can make/lose money.

Speculation

The Price per Share of MoonLake Immunotherapeutics is $44.07. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of MoonLake Immunotherapeutics.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in MoonLake Immunotherapeutics, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $7.86. Based on the TTM, the Book Value Change Per Share is $0.02 per quarter. Based on the YOY, the Book Value Change Per Share is $1.61 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of MoonLake Immunotherapeutics.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-0.56-1.3%-0.32-0.7%-0.21-0.5%-0.21-0.5%-0.21-0.5%
Usd Book Value Change Per Share-0.55-1.2%0.020.1%1.613.7%0.521.2%0.521.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.55-1.2%0.020.1%1.613.7%0.521.2%0.521.2%
Usd Price Per Share50.42-51.25-34.97-27.29-27.29-
Price to Earnings Ratio-22.46--59.24--54.68--183.83--183.83-
Price-to-Total Gains Ratio-92.08-6.25--140.02--58.68--58.68-
Price to Book Ratio6.42-6.20-11.56-4.85-4.85-
Price-to-Total Gains Ratio-92.08-6.25--140.02--58.68--58.68-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share44.07
Number of shares22
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.020.52
Usd Total Gains Per Share0.020.52
Gains per Quarter (22 shares)0.5111.52
Gains per Year (22 shares)2.0446.10
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
102-804636
204-609282
306-40138128
408-20184174
501000230220
601220277266
701440323312
801660369358
901880415404
10020100461450

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%0.012.00.00.0%0.015.00.00.0%0.015.00.00.0%0.015.00.00.0%
Book Value Change Per Share2.02.00.050.0%5.07.00.041.7%6.08.01.040.0%6.08.01.040.0%6.08.01.040.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.015.00.0%0.00.015.00.0%0.00.015.00.0%
Total Gains per Share2.02.00.050.0%5.07.00.041.7%6.08.01.040.0%6.08.01.040.0%6.08.01.040.0%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of MoonLake Immunotherapeutics compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.5480.023-2457%1.614-134%0.524-205%0.524-205%
Book Value Per Share--7.8578.291-5%4.427+77%3.946+99%3.946+99%
Current Ratio--25.51245.737-44%34.649-26%25.087+2%25.087+2%
Debt To Asset Ratio--0.0440.029+50%0.064-32%0.247-82%0.247-82%
Debt To Equity Ratio--0.0470.031+51%0.097-52%0.721-94%0.721-94%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--3650894841.0003734544908.250-2%2480272638.750+47%1931738294.867+89%1931738294.867+89%
Eps---0.561-0.320-43%-0.213-62%-0.210-63%-0.210-63%
Ev To Ebitda Ratio---21.187-41.606+96%-46.755+121%infnan%infnan%
Ev To Sales Ratio--infinfnan%infnan%infnan%infnan%
Free Cash Flow Per Share---0.403-0.321-20%-0.167-59%-0.180-55%-0.180-55%
Free Cash Flow To Equity Per Share---0.400-0.006-99%3.411-112%1.153-135%1.153-135%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---28.453--------
Intrinsic Value_10Y_min---23.938--------
Intrinsic Value_1Y_max---1.173--------
Intrinsic Value_1Y_min---1.151--------
Intrinsic Value_3Y_max---4.803--------
Intrinsic Value_3Y_min---4.560--------
Intrinsic Value_5Y_max---9.976--------
Intrinsic Value_5Y_min---9.149--------
Market Cap2779226073.000-14%3179681838.0003232182534.750-2%2205502242.750+44%1721224044.000+85%1721224044.000+85%
Net Profit Margin----267.3870%-0%-71.3030%-71.3030%
Operating Margin----441.4000%-0%-117.7070%-117.7070%
Operating Ratio---441.400-100%-0%117.707-100%117.707-100%
Pb Ratio5.609-14%6.4176.200+4%11.559-44%4.854+32%4.854+32%
Pe Ratio-19.633+13%-22.462-59.242+164%-54.675+143%-183.830+718%-183.830+718%
Price Per Share44.070-14%50.42051.253-2%34.973+44%27.293+85%27.293+85%
Price To Free Cash Flow Ratio-27.347+13%-31.287-45.943+47%-53.730+72%1611.979-102%1611.979-102%
Price To Total Gains Ratio-80.488+13%-92.0856.252-1573%-140.015+52%-58.680-36%-58.680-36%
Quick Ratio--30.60654.093-43%40.008-24%151.386-80%151.386-80%
Return On Assets---0.068-0.038-45%-0.109+60%-0.104+53%-0.104+53%
Return On Equity---0.072-0.040-45%-0.168+131%-0.570+687%-0.570+687%
Total Gains Per Share---0.5480.023-2457%1.614-134%0.524-205%0.524-205%
Usd Book Value--495501640.000522852636.000-5%279157747.000+77%248869884.000+99%248869884.000+99%
Usd Book Value Change Per Share---0.5480.023-2457%1.614-134%0.524-205%0.524-205%
Usd Book Value Per Share--7.8578.291-5%4.427+77%3.946+99%3.946+99%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--3650894841.0003734544908.250-2%2480272638.750+47%1931738294.867+89%1931738294.867+89%
Usd Eps---0.561-0.320-43%-0.213-62%-0.210-63%-0.210-63%
Usd Free Cash Flow---25407002.000-20271625.500-20%-10507456.000-59%-11331243.533-55%-11331243.533-55%
Usd Free Cash Flow Per Share---0.403-0.321-20%-0.167-59%-0.180-55%-0.180-55%
Usd Free Cash Flow To Equity Per Share---0.400-0.006-99%3.411-112%1.153-135%1.153-135%
Usd Market Cap2779226073.000-14%3179681838.0003232182534.750-2%2205502242.750+44%1721224044.000+85%1721224044.000+85%
Usd Price Per Share44.070-14%50.42051.253-2%34.973+44%27.293+85%27.293+85%
Usd Profit---35390337.000-20192020.250-43%-12063061.250-66%-14549098.000-59%-14549098.000-59%
Usd Revenue---9869.000-100%-0%2631.733-100%2631.733-100%
Usd Total Gains Per Share---0.5480.023-2457%1.614-134%0.524-205%0.524-205%
 EOD+3 -5MRQTTM+3 -31YOY+15 -175Y+15 -1810Y+15 -18

3.3 Fundamental Score

Let's check the fundamental score of MoonLake Immunotherapeutics based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-19.633
Price to Book Ratio (EOD)Between0-15.609
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than130.606
Current Ratio (MRQ)Greater than125.512
Debt to Asset Ratio (MRQ)Less than10.044
Debt to Equity Ratio (MRQ)Less than10.047
Return on Equity (MRQ)Greater than0.15-0.072
Return on Assets (MRQ)Greater than0.05-0.068
Total4/10 (40.0%)

3.4 Technical Score

Let's check the technical score of MoonLake Immunotherapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose45.180
Total1/1 (100.0%)

4. In-depth Analysis

4.1 About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.

Fundamental data was last updated by Penke on 2025-02-08 01:13:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit MoonLake Immunotherapeutics earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare MoonLake Immunotherapeutics to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of MoonLake Immunotherapeutics:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-26,738.7%+26,738.7%
TTM-26,738.7%YOY--26,738.7%
TTM-26,738.7%5Y-7,130.3%-19,608.4%
5Y-7,130.3%10Y-7,130.3%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--100.3%+100.3%
TTM-26,738.7%-211.9%-26,526.8%
YOY--207.4%+207.4%
5Y-7,130.3%-340.4%-6,789.9%
10Y-7,130.3%-486.1%-6,644.2%
4.3.1.2. Return on Assets

Shows how efficient MoonLake Immunotherapeutics is using its assets to generate profit.

  • Above 5% is considered healthy but always compare MoonLake Immunotherapeutics to the Biotechnology industry mean.
  • -6.8% Return on Assets means that MoonLake Immunotherapeutics generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of MoonLake Immunotherapeutics:

  • The MRQ is -6.8%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.8%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.8%TTM-3.8%-3.0%
TTM-3.8%YOY-10.9%+7.1%
TTM-3.8%5Y-10.4%+6.6%
5Y-10.4%10Y-10.4%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.8%-12.3%+5.5%
TTM-3.8%-12.3%+8.5%
YOY-10.9%-11.8%+0.9%
5Y-10.4%-13.2%+2.8%
10Y-10.4%-15.2%+4.8%
4.3.1.3. Return on Equity

Shows how efficient MoonLake Immunotherapeutics is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare MoonLake Immunotherapeutics to the Biotechnology industry mean.
  • -7.2% Return on Equity means MoonLake Immunotherapeutics generated $-0.07 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of MoonLake Immunotherapeutics:

  • The MRQ is -7.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.0%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.2%TTM-4.0%-3.3%
TTM-4.0%YOY-16.8%+12.8%
TTM-4.0%5Y-57.0%+53.1%
5Y-57.0%10Y-57.0%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.2%-15.9%+8.7%
TTM-4.0%-16.7%+12.7%
YOY-16.8%-15.1%-1.7%
5Y-57.0%-19.2%-37.8%
10Y-57.0%-20.5%-36.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of MoonLake Immunotherapeutics.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient MoonLake Immunotherapeutics is operating .

  • Measures how much profit MoonLake Immunotherapeutics makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare MoonLake Immunotherapeutics to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of MoonLake Immunotherapeutics:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-44,140.0%+44,140.0%
TTM-44,140.0%YOY--44,140.0%
TTM-44,140.0%5Y-11,770.7%-32,369.3%
5Y-11,770.7%10Y-11,770.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--201.1%+201.1%
TTM-44,140.0%-313.4%-43,826.6%
YOY--217.7%+217.7%
5Y-11,770.7%-357.2%-11,413.5%
10Y-11,770.7%-481.3%-11,289.4%
4.3.2.2. Operating Ratio

Measures how efficient MoonLake Immunotherapeutics is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of MoonLake Immunotherapeutics:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM441.400-441.400
TTM441.400YOY-+441.400
TTM441.4005Y117.707+323.693
5Y117.70710Y117.7070.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.153-2.153
TTM441.4003.220+438.180
YOY-3.279-3.279
5Y117.7074.740+112.967
10Y117.7076.433+111.274
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of MoonLake Immunotherapeutics.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if MoonLake Immunotherapeutics is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 25.51 means the company has $25.51 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of MoonLake Immunotherapeutics:

  • The MRQ is 25.512. The company is very able to pay all its short-term debts. +2
  • The TTM is 45.737. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ25.512TTM45.737-20.224
TTM45.737YOY34.649+11.087
TTM45.7375Y25.087+20.649
5Y25.08710Y25.0870.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ25.5123.613+21.899
TTM45.7373.864+41.873
YOY34.6494.600+30.049
5Y25.0875.977+19.110
10Y25.0876.216+18.871
4.4.3.2. Quick Ratio

Measures if MoonLake Immunotherapeutics is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare MoonLake Immunotherapeutics to the Biotechnology industry mean.
  • A Quick Ratio of 30.61 means the company can pay off $30.61 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of MoonLake Immunotherapeutics:

  • The MRQ is 30.606. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 54.093. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ30.606TTM54.093-23.487
TTM54.093YOY40.008+14.085
TTM54.0935Y151.386-97.293
5Y151.38610Y151.3860.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ30.6063.042+27.564
TTM54.0933.360+50.733
YOY40.0084.358+35.650
5Y151.3865.973+145.413
10Y151.3866.492+144.894
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of MoonLake Immunotherapeutics.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of MoonLake Immunotherapeutics assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare MoonLake Immunotherapeutics to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.04 means that MoonLake Immunotherapeutics assets are financed with 4.4% credit (debt) and the remaining percentage (100% - 4.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of MoonLake Immunotherapeutics:

  • The MRQ is 0.044. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.029. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.044TTM0.029+0.015
TTM0.029YOY0.064-0.035
TTM0.0295Y0.247-0.218
5Y0.24710Y0.2470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0440.341-0.297
TTM0.0290.341-0.312
YOY0.0640.316-0.252
5Y0.2470.363-0.116
10Y0.2470.384-0.137
4.5.4.2. Debt to Equity Ratio

Measures if MoonLake Immunotherapeutics is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare MoonLake Immunotherapeutics to the Biotechnology industry mean.
  • A Debt to Equity ratio of 4.7% means that company has $0.05 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of MoonLake Immunotherapeutics:

  • The MRQ is 0.047. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.031. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.047TTM0.031+0.016
TTM0.031YOY0.097-0.066
TTM0.0315Y0.721-0.691
5Y0.72110Y0.7210.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0470.385-0.338
TTM0.0310.428-0.397
YOY0.0970.391-0.294
5Y0.7210.450+0.271
10Y0.7210.493+0.228
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings MoonLake Immunotherapeutics generates.

  • Above 15 is considered overpriced but always compare MoonLake Immunotherapeutics to the Biotechnology industry mean.
  • A PE ratio of -22.46 means the investor is paying $-22.46 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of MoonLake Immunotherapeutics:

  • The EOD is -19.633. Based on the earnings, the company is expensive. -2
  • The MRQ is -22.462. Based on the earnings, the company is expensive. -2
  • The TTM is -59.242. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-19.633MRQ-22.462+2.829
MRQ-22.462TTM-59.242+36.780
TTM-59.242YOY-54.675-4.566
TTM-59.2425Y-183.830+124.588
5Y-183.83010Y-183.8300.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-19.633-2.266-17.367
MRQ-22.462-2.889-19.573
TTM-59.242-3.313-55.929
YOY-54.675-3.371-51.304
5Y-183.830-6.132-177.698
10Y-183.830-6.688-177.142
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of MoonLake Immunotherapeutics:

  • The EOD is -27.347. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -31.287. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -45.943. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-27.347MRQ-31.287+3.940
MRQ-31.287TTM-45.943+14.655
TTM-45.943YOY-53.730+7.788
TTM-45.9435Y1,611.979-1,657.922
5Y1,611.97910Y1,611.9790.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-27.347-3.049-24.298
MRQ-31.287-3.718-27.569
TTM-45.943-3.896-42.047
YOY-53.730-4.498-49.232
5Y1,611.979-8.210+1,620.189
10Y1,611.979-9.262+1,621.241
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of MoonLake Immunotherapeutics is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 6.42 means the investor is paying $6.42 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of MoonLake Immunotherapeutics:

  • The EOD is 5.609. Based on the equity, the company is overpriced. -1
  • The MRQ is 6.417. Based on the equity, the company is overpriced. -1
  • The TTM is 6.200. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD5.609MRQ6.417-0.808
MRQ6.417TTM6.200+0.217
TTM6.200YOY11.559-5.359
TTM6.2005Y4.854+1.346
5Y4.85410Y4.8540.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD5.6091.918+3.691
MRQ6.4172.261+4.156
TTM6.2002.471+3.729
YOY11.5592.469+9.090
5Y4.8543.769+1.085
10Y4.8544.477+0.377
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of MoonLake Immunotherapeutics.

4.8.1. Institutions holding MoonLake Immunotherapeutics

Institutions are holding 98.133% of the shares of MoonLake Immunotherapeutics.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-09-30Bvf Inc34.490832.08282175128400
2024-09-30Cormorant Asset Management, LLC13.469122.711849415100
2024-09-30FMR Inc7.84950.01524950224130621535.8455
2024-09-30T. Rowe Price Associates, Inc.4.72580.0173298024941873716.3473
2024-09-30venBio Select Advisor LLC4.39252.036527701001000.0036
2024-09-30Citadel Advisors Llc3.68350.02262322971572762.528
2024-09-30Holocene Advisors, LP2.51360.32281585167-41174-2.5317
2024-09-30Goldman Sachs Group Inc2.37190.0121149583124408419.4995
2024-09-30Westfield Capital Management Company, L.P.1.85110.26591167358497334.4499
2024-09-30Marshall Wace Asset Management Ltd1.83050.07091154385557555.075
2024-09-30Federated Hermes Inc1.79240.1251113032819000.1684
2024-09-30AllianceBernstein L.P.1.58270.0169998140-23610-2.3107
2024-09-30Paradigm Biocapital Advisors LP1.4771.58899314809314800
2024-09-30Fred Alger Management, LLC1.0570.162966657475451.1449
2024-09-30Hood River Capital Management LLC1.02540.52646466626466620
2024-09-30Nuveen Asset Management, LLC0.9210.00825807895907611.3235
2024-09-30Adage Capital Partners Gp LLC0.80080.045505000-1320000-72.3288
2024-09-30Polar Capital Holdings PLC0.79280.1203500000-178169-26.2721
2024-09-30Camber Capital Management LLC0.69930.70624410008600024.2254
2024-09-30ING Investment Management LLC0.64890.0214409203350958602.5547
Total 87.975660.878455480896+2652568+4.8%

4.9.2. Funds holding MoonLake Immunotherapeutics

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-12-31T. Rowe Price Health Sciences2.48080.649615644791275678.8779
2024-12-31Polar Capital Biotech S Inc1.58572.8395100000000
2024-12-31Fidelity Select Health Care1.09410.551569000000
2024-12-31Fidelity Growth Compy Commingled Pl S1.08620.039168499669431.024
2024-12-31T. Rowe Price New Horizons1.05790.182366717600
2024-12-31US Small-Cap Growth II Equity Comp1.05790.1823667176-574-0.086
2024-12-31Westfield Capital Mgt Co Sm-Cap Gr Eq1.02761.755864806911097020.661
2024-12-31Harbor Small Cap Growth Instl1.02761.70236480699764017.7389
2024-12-31T. Rowe Price Integrated US SmCapGrEq0.94870.1907598314299157100
2024-09-30Federated Hermes Kaufmann Growth0.88010.548655500000
2024-09-30Federated Hermes Kaufmann R0.88010.548455500000
2024-12-31Fidelity Select Biotechnology0.81010.651251085800
2024-10-31Alger Small Cap Focus Composite0.76681.842948356500
2024-10-31Alger Small Cap Focus I0.76681.842948356500
2024-12-31Fidelity Growth Company Fund0.75850.038478335-5817-1.2015
2024-09-30Federated Hermes Kaufmann Small Cap Grow0.74730.595947127600
2024-09-30Federated Hermes Kaufmann Small Cap A0.74730.595947127600
2024-12-31Fidelity Advisor Health Care I0.67390.566242500000
2024-12-31Fidelity Blue Chip Growth0.6230.028839285800
2024-09-30Hood River Small-Cap Growth Instl0.5740.51463620063620060
Total 19.594415.866512357018+997892+8.1%

5.3. Insider Transactions

Insiders are holding 15.225% of the shares of MoonLake Immunotherapeutics.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-10-04Simon SturgeSELL17100053.72
2024-02-29Da Silva Jorge SantosSELL474055.89
2024-02-27Da Silva Jorge SantosSELL6281055
2024-02-27Kristian ReichSELL2943155
2024-02-20Da Silva Jorge SantosSELL2000057.44
2024-02-20Kristian ReichSELL1000057.43
2024-02-16Kristian ReichSELL1000060.15
2024-02-15Da Silva Jorge SantosSELL2000060.18
2024-02-14Kristian ReichSELL1000062.43
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets518,213
Total Liabilities22,712
Total Stockholder Equity488,195
 As reported
Total Liabilities 22,712
Total Stockholder Equity+ 488,195
Total Assets = 518,213

Assets

Total Assets518,213
Total Current Assets512,316
Long-term Assets5,897
Total Current Assets
Cash And Cash Equivalents 375,656
Short-term Investments 118,268
Net Receivables 2,407
Other Current Assets 15,984
Total Current Assets  (as reported)512,316
Total Current Assets  (calculated)512,316
+/-0
Long-term Assets
Property Plant Equipment 3,833
Long-term Assets Other 2,065
Long-term Assets  (as reported)5,897
Long-term Assets  (calculated)5,897
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities20,081
Long-term Liabilities2,631
Total Stockholder Equity488,195
Total Current Liabilities
Short-term Debt 1,752
Accounts payable 104
Other Current Liabilities 17,740
Total Current Liabilities  (as reported)20,081
Total Current Liabilities  (calculated)19,597
+/- 484
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt1,936
Long-term Liabilities  (as reported)2,631
Long-term Liabilities  (calculated)1,936
+/- 695
Total Stockholder Equity
Common Stock6
Retained Earnings -189,988
Accumulated Other Comprehensive Income 2,834
Other Stockholders Equity 675,343
Total Stockholder Equity (as reported)488,195
Total Stockholder Equity (calculated)488,195
+/-0
Other
Capital Stock6
Cash and Short Term Investments 493,925
Common Stock Shares Outstanding 62,897
Liabilities and Stockholders Equity 518,213
Net Debt -371,968
Net Invested Capital 488,195
Net Working Capital 492,235
Property Plant and Equipment Gross 3,833
Short Long Term Debt Total 3,688



5.2. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-31
> Total Assets 
116,634
0
116,247
9,682
231,210
98,434
88,592
76,843
66,797
506,621
500,219
526,540
564,117
544,878
518,213
518,213544,878564,117526,540500,219506,62166,79776,84388,59298,434231,2109,682116,2470116,634
   > Total Current Assets 
1,619
0
1,207
9,637
116,159
98,378
88,539
76,511
66,504
506,367
500,010
514,167
553,590
536,882
512,316
512,316536,882553,590514,167500,010506,36766,50476,51188,53998,378116,1599,6371,20701,619
       Cash And Cash Equivalents 
1,336
0
1,029
8,039
23
92,708
41,205
39,506
50,129
501,787
318,166
451,169
458,441
342,791
375,656
375,656342,791458,441451,169318,166501,78750,12939,50641,20592,708238,0391,02901,336
       Short-term Investments 
115,015
0
0
0
0
0
42,255
32,609
12,921
0
177,813
59,839
88,614
177,008
118,268
118,268177,00888,61459,839177,813012,92132,60942,25500000115,015
       Net Receivables 
0
0
67
149
15,000
557
601
217
378
620
721
1,057
1,496
1,677
2,407
2,4071,6771,4961,05772162037821760155715,0001496700
       Other Current Assets 
0
0
178
1,449
116,136
5,113
4,479
4,179
3,076
3,960
3,310
2,102
5,039
15,406
15,984
15,98415,4065,0392,1023,3103,9603,0764,1794,4795,113116,1361,44917800
   > Long-term Assets 
115,015
0
115,040
46
115,051
56
53
332
292
254
209
12,373
10,527
7,996
5,897
5,8977,99610,52712,3732092542923325356115,05146115,0400115,015
       Property Plant Equipment 
0
0
30
46
59
56
53
332
292
254
209
3,949
4,208
3,867
3,833
3,8333,8674,2083,949209254292332535659463000
       Long-term Assets Other 
115,015
0
0
115,043
115,051
0
0
0
0
211
0
8,423
6,319
4,129
2,065
2,0654,1296,3198,42302110000115,051115,04300115,015
> Total Liabilities 
4,150
0
6,084
21,327
206,815
3,876
6,024
8,077
7,685
7,511
10,577
13,049
11,731
14,846
22,712
22,71214,84611,73113,04910,5777,5117,6858,0776,0243,876206,81521,3276,08404,150
   > Total Current Liabilities 
125
0
2,059
21,088
202,790
3,857
6,019
7,665
7,279
7,135
10,308
9,966
8,911
12,282
20,081
20,08112,2828,9119,96610,3087,1357,2797,6656,0193,857202,79021,0882,0590125
       Short-term Debt 
0
0
0
15,000
0
0
42,255
154
155
158
156
1,198
1,304
2,643
1,752
1,7522,6431,3041,19815615815515442,2550015,000000
       Short Long Term Debt 
0
0
0
15,000
0
0
0
0
0
0
0
0
0
0
0
0000000000015,000000
       Accounts payable 
0
0
96
1,428
213
649
680
255
511
271
824
553
1,630
56
104
104561,6305538242715112556806492131,4289600
       Other Current Liabilities 
125
0
2,059
4,659
202,790
3,208
5,339
7,257
6,614
6,976
9,328
8,400
5,125
8,964
17,740
17,7408,9645,1258,4009,3286,9766,6147,2575,3393,208202,7904,6592,0590125
   > Long-term Liabilities 
4,025
0
4,025
240
4,025
19
5
411
405
377
268
3,083
2,820
2,564
2,631
2,6312,5642,8203,0832683774054115194,0252404,02504,025
       Warrants
0
0
0
115,000
0
0
0
0
0
0
0
0
0
0
0
00000000000115,000000
       Other Liabilities 
0
0
150
240
4,025
19
5
282
0
324
0
0
0
0
0
0000032402825194,02524015000
       Deferred Long Term Liability 
0
0
0
4,025
0
0
0
0
0
0
0
0
0
0
0
000000000004,025000
> Total Stockholder Equity
5,000
0
-4,837
-11,645
24,395
63,515
55,288
48,898
41,999
489,797
424,933
495,676
542,554
520,664
488,195
488,195520,664542,554495,676424,933489,79741,99948,89855,28863,51524,395-11,645-4,83705,000
   Common Stock
107,484
0
115,000
39
231,211
5
5
5
5
6
6
6
6
6
6
6666665555231,21139115,0000107,484
   Retained Earnings -189,988-154,598-130,331-116,657-109,220-99,794-89,655-80,650-68,788-58,678-9,763-53,644-4,8370-91
   Capital Surplus 
0
0
0
0
0
122,054
123,826
129,192
131,309
589,550
0
0
0
0
0
00000589,550131,309129,192123,826122,05400000
   Treasury Stock000000000000000
   Other Stockholders Equity 
-102,393
0
-115,000
42,056
-197,053
122,054
123,826
129,192
131,309
589,550
531,272
609,969
670,185
671,999
675,343
675,343671,999670,185609,969531,272589,550131,309129,192123,826122,054-197,05342,056-115,0000-102,393



5.3. Balance Sheets

Currency in USD. All numbers in thousands.




5.4. Cash Flows

Currency in USD. All numbers in thousands.




5.5. Income Statements

Currency in USD. All numbers in thousands.


5.6. Latest Income Statement

Income Statement (annual), 2023-12-31. Currency in USD. All numbers in thousands.

Gross Profit (+$)
totalRevenue0
Cost of Revenue-13
Gross Profit-13-13
 
Operating Income (+$)
Gross Profit-13
Operating Expense-54,123
Operating Income-54,123-54,136
 
Operating Expense (+$)
Research Development31,789
Selling General Administrative22,321
Selling And Marketing Expenses22,298,895
Operating Expense54,12322,353,005
 
Net Interest Income (+$)
Interest Income0
Interest Expense-0
Other Finance Cost-0
Net Interest Income0
 
Pretax Income (+$)
Operating Income-54,123
Net Interest Income0
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-43,985-64,261
EBIT - interestExpense = -54,123
-35,913
-36,007
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-54,123-43,985
Earnings Before Interest and Taxes (EBITDA)-54,110
 
After tax Income (+$)
Income Before Tax-43,985
Tax Provision-61
Net Income From Continuing Ops-52,660-44,046
Net Income-36,007
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses54,123
Total Other Income/Expenses Net10,1380
 

Technical Analysis of MoonLake Immunotherapeutics
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of MoonLake Immunotherapeutics. The general trend of MoonLake Immunotherapeutics is UNKNOWN with 0.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine MoonLake Immunotherapeutics's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator StateBullish trend Bearish trend
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of MoonLake Immunotherapeutics.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 47.33 < 50.21 < 56.00.

The bearish price targets are: 41.27 > 39.36 > 38.38.

Tweet this
MoonLake Immunotherapeutics Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of MoonLake Immunotherapeutics. The current mas is .

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

MoonLake Immunotherapeutics Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics Daily Moving Average Convergence/Divergence (MACD) ChartMoonLake Immunotherapeutics Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of MoonLake Immunotherapeutics. The current adx is .

MoonLake Immunotherapeutics Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics Daily Parabolic SAR Chart
3rd party ad coffee SUPPORTERis ad-free.

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics Daily Relative Strength Index (RSI) ChartMoonLake Immunotherapeutics Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics Daily Stochastic Oscillator ChartMoonLake Immunotherapeutics Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics Daily Commodity Channel Index (CCI) ChartMoonLake Immunotherapeutics Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics Daily Chande Momentum Oscillator (CMO) ChartMoonLake Immunotherapeutics Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics Daily Williams %R ChartMoonLake Immunotherapeutics Daily Williams %R Chart
3rd party ad coffee SUPPORTERis ad-free.

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics Daily Average True Range (ATR) ChartMoonLake Immunotherapeutics Daily Average True Range (ATR) Chart
3rd party ad coffee SUPPORTERis ad-free.

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics Daily On-Balance Volume (OBV) ChartMoonLake Immunotherapeutics Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of MoonLake Immunotherapeutics.

MoonLake Immunotherapeutics Daily Money Flow Index (MFI) ChartMoonLake Immunotherapeutics Daily Money Flow Index (MFI) Chart
3rd party ad coffee SUPPORTERis ad-free.

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for MoonLake Immunotherapeutics.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2024-09-18CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-23BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-09-24RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
2024-09-25CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-09-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-09-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-10-01STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-10-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-04MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-10-07MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-10-08CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-09DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-10-10WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-10-15STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-10-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-23DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-10-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-10-30STOCH LONG EXITThe %K line crosses below the %D line.
2024-10-31CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-11-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-07SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-11-08WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-11-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-14STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-11-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-11-19STOCH SHORT EXITThe %K line crosses above the %D line.
2024-11-20MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-11-21MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-11-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-11-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-11-29CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-03STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-04CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-06WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-12-09MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-12-13SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-16STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-12-18STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-12-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-12-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-12-26CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-12-27MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-12-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-12-31CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-06DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2025-01-07BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-15STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2025-01-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-22SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2025-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2025-01-28STOCH SHORT EXITThe %K line crosses above the %D line.
2025-01-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2025-01-30CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-01-31STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2025-02-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2025-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2025-02-06DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2025-02-07DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside

6.3. Candlestick Patterns

MoonLake Immunotherapeutics Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of MoonLake Immunotherapeutics based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose45.180
Total1/1 (100.0%)
Penke
Good job! You gained 25 XP and 0   0   10 . What's next:
  • Share my analysis of MoonLake Immunotherapeutics with someone you think should read this too:
  • Are you bullish or bearish on MoonLake Immunotherapeutics? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about MoonLake Immunotherapeutics? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about MoonLake Immunotherapeutics

I send you an email if I find something interesting about MoonLake Immunotherapeutics.


Comments

How you think about this?

Leave a comment

Stay informed about MoonLake Immunotherapeutics.

Receive notifications about MoonLake Immunotherapeutics in your mailbox!

3rd party ad coffee SUPPORTERis ad-free.